2014

China Human Vaccine Industry Report 2013

DUBLIN, Dec. 6, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/srtkcw/china_human) has announced the addition of the "China Human Vaccine Industry Report 2013" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions.

Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market.

However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each.

In recent years, China has made some achievements in overseas vaccine markets. In 2011-2012, China's annual human vaccine export volume remained over 9,000 tons (9,840 tons in 2010 was subject to the accidental H1N1 flu event), far more than 8,110 tons in 2009. Moreover, many domestic vaccine companies are still planning overseas markets aggressively.

By the end of 2012, the first batch of Hib vaccine products of Walvax Biotechnology were approved by China Customs and exported to Manila, Philippines for official marketing. Walvax Biotechnology is promoting the product registration in Russia, India, Thailand and other countries. In November 2012, Hualan Biological Engineering mailed three consecutive batches of samples for influenza virus split vaccine to WHO for testing. The company is expected to receive WHO's spot verification certification in 2013. On March 7, 2013, Tiantan Biological obtained the production approval for polio attenuated live vaccine (liquid OPV). In accordance with the cooperation agreement with Bill & Melinda Gates Foundation in 2011, Tiantan Biological will supply OPV to United Nations International Children's Emergency Fund (UNICEF) formally.

In addition, it is worth mentioning that the industrialization of the world's first recombinant hepatitis E vaccine (Escherichia coli) developed by Xiamen University and YangShengTang INNOVAX jointly was realized on October 27, 2012. As of the end of 2012, the lot release quantity of the product hit 90,000 person-portions.

Key Topics Covered:

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. Overview of China Human Vaccine Industry
2.1 Overview
2.2 Operating Environment
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Outlook
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccine
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DPT Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Situation & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern

4. Human Vaccine Import and Export in China
4.1 Export
4.2 Import

5. Major Human Vaccine Producers in China

Companies Mentioned:

  • Beijing Tiantan Biological Products
  • Changchun BCHT Biotechnology
  • Changchun Changsheng Life Sciences Limited
  • China National Biotec Group
  • Chongqing Zhifei Biological Products
  • Dalian Hissen Bio-Pharm
  • Hualan Biological Engineering
  • Liaoning Chengda
  • Shenzhen Kangtai Biological Products
  • Sinovac Biotech
  • Yunnan Walvax Biotechnology
  • Zhejiang Tianyuan Bio-Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/srtkcw/china_human.

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS
http://www.researchandmarkets.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.